These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34184163)

  • 1. Development of Spray-Dried Cyclodextrin-Based Pediatric Anti-HIV Formulations.
    Ivone R; Fernando A; DeBoef B; Meenach SA; Shen J
    AAPS PharmSciTech; 2021 Jun; 22(5):193. PubMed ID: 34184163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of nanoparticle-based orodispersible palatable pediatric formulations.
    Deng Y; Shen L; Yang Y; Shen J
    Int J Pharm; 2021 Mar; 596():120206. PubMed ID: 33493595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assembly nanoparticles.
    Pham K; Li D; Guo S; Penzak S; Dong X
    J Control Release; 2016 Mar; 226():88-97. PubMed ID: 26849919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe.
    Pasipanodya B; Kuwengwa R; Prust ML; Stewart B; Chakanyuka C; Murimwa T; Brophy J; Salami O; Mushavi A; Apollo T
    J Int AIDS Soc; 2018 Dec; 21(12):e25214. PubMed ID: 30549217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
    Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spray-dried mucoadhesive microparticles based on S-protected thiolated hydroxypropyl-β-cyclodextrin for budesonide nasal delivery.
    Racaniello GF; Laquintana V; Summonte S; Lopedota A; Cutrignelli A; Lopalco A; Franco M; Bernkop-Schnürch A; Denora N
    Int J Pharm; 2021 Jun; 603():120728. PubMed ID: 34029665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug.
    Nassar T; Rohald A; Naraykin N; Barasch D; Amsalem O; Prabhu P; Kotler M; Benita S
    J Drug Target; 2019; 27(5-6):590-600. PubMed ID: 30470150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs: A Case Study of Lopinavir/Ritonavir.
    Saeed AM; Schmidt JM; Munasinghe WP; Vallabh BK; Jarvis MF; Morris JB; Mostafa NM
    J Pharm Sci; 2021 Dec; 110(12):3963-3968. PubMed ID: 34530003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
    AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.
    Mangal S; Nie H; Xu R; Guo R; Cavallaro A; Zemlyanov D; Zhou QT
    Pharm Res; 2018 Jan; 35(2):28. PubMed ID: 29374368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the hydrophobic nature of triacetyl-beta-cyclodextrin on the complexation with nicardipine hydrochloride: physicochemical and dissolution properties of the kneaded and spray-dried complexes.
    Fernandes CM; Veiga FJ
    Chem Pharm Bull (Tokyo); 2002 Dec; 50(12):1597-602. PubMed ID: 12499598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
    Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
    BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
    Ruel TD; Kakuru A; Ikilezi G; Mwangwa F; Dorsey G; Rosenthal PJ; Charlebois E; Havlir D; Kamya M; Achan J
    J Acquir Immune Defic Syndr; 2014 Apr; 65(5):535-41. PubMed ID: 24326597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
    Camacho Á; Rivero A
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.
    Robbins BL; Capparelli EV; Chadwick EG; Yogev R; Serchuck L; Worrell C; Smith ME; Alvero C; Fenton T; Heckman B; Pelton SI; Aldrovandi G; Borkowsky W; Rodman J; Havens PL;
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3276-83. PubMed ID: 18625762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.